Array BioPharma (ARRY) stock price, revenue, and financials

Array BioPharma market cap is $10.7 b, and annual revenue was $173.77 m in FY 2018

$10.7 B

ARRY Mkt cap, 30-Jul-2019

$64.7 M

Array BioPharma Revenue Q3, 2019
Array BioPharma Gross profit (Q3, 2019)63.6 M
Array BioPharma Gross profit margin (Q3, 2019), %98.4%
Array BioPharma Net income (Q3, 2019)-37.5 M
Array BioPharma EBIT (Q3, 2019)-37.5 M
Array BioPharma Cash, 31-Mar-201996.6 M
Array BioPharma EV10.7 B

Array BioPharma Revenue

Array BioPharma revenue was $173.77 m in FY, 2018

Embed Graph

Array BioPharma Income Statement

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Revenue

22.1m23.2m19.1m15.8m18.4m10.0m14.2m14.1m7.8m6.1m26.9m6.6m16.2m35.4m43.0m39.3m44.5m33.3m29.7m42.2m66.4m56.9m82.5m64.7m

Cost of goods sold

6.4m6.3m5.3m6.5m7.9m8.6m10.7m10.8m12.2m13.1m12.1m6.2m5.7m5.8m8.8m9.0m7.4m11.8m13.7m17.7m195.0k786.0k1.0m

Gross profit

15.7m17.0m13.8m9.3m10.5m1.3m3.6m(3.0m)(6.1m)13.8m(5.5m)10.0m29.8m37.2m30.4m35.5m25.8m18.0m28.5m48.7m56.7m81.8m63.6m

Gross profit Margin, %

71%73%72%59%57%13%25%(38%)(101%)51%(84%)62%84%86%77%80%78%60%68%73%100%99%98%

R&D expense

12.6m13.2m16.1m13.5m13.9m15.1m11.7m14.1m12.2m11.8m11.8m21.0m41.4m48.8m46.6m46.5m46.1m41.4m42.6m53.6m55.6m62.1m65.5m

General and administrative expense

3.7m3.8m3.2m4.8m4.6m5.0m5.2m5.5m5.4m6.8m8.1m8.2m7.4m9.9m8.4m7.9m8.8m11.7m12.0m11.6m16.8m24.9m30.5m35.5m

Operating expense total

16.3m16.9m19.3m18.3m18.6m20.1m16.9m28.1m19.5m19.0m19.9m(60.0m)28.4m51.3m57.2m54.4m55.3m57.8m53.5m54.2m70.4m80.4m92.6m101.1m

EBIT

(631.0k)30.0k(5.5m)(9.0m)(8.1m)(18.8m)(13.3m)(14.0m)(22.5m)(25.1m)(6.1m)54.5m(18.4m)(21.5m)(20.0m)(24.0m)(19.8m)(31.9m)(35.5m)(25.7m)(21.8m)(23.7m)(10.8m)(37.5m)

EBIT margin, %

(3%)0%(29%)(57%)(44%)(189%)(94%)(100%)(290%)(414%)(23%)825%(113%)(61%)(46%)(61%)(44%)(96%)(119%)(61%)(33%)(42%)(13%)(58%)

Interest expense

3.0m3.8m2.7m2.8m2.9m2.8m2.4m2.4m2.5m3.8m2.6m2.6m2.7m4.6m3.5m3.4m2.5m8.3m1.1m1.1m532.0k40.0k

Interest income

6.0k3.0k8.0k11.0k12.0k18.0k16.0k23.0k22.0k13.0k8.0k15.0k40.0k51.0k76.0k70.0k212.0k228.0k525.0k1.3m1.3m1.5m2.3m2.9m

Pre tax profit

(10.9m)

Net Income

(3.6m)(3.8m)(8.2m)(11.8m)(10.9m)(21.6m)(15.7m)(16.4m)(24.9m)(27.6m)(8.6m)58.3m(21.0m)(24.2m)(22.7m)(28.6m)(23.3m)(35.3m)(38.0m)(34.1m)(22.9m)(24.8m)(11.4m)(37.5m)

Array BioPharma Balance Sheet

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

55.8m60.7m68.6m55.7m56.6m125.9m114.7m

Accounts Receivable

9.6m5.4m6.3m39.3m31.3m32.1m

Prepaid Expenses

3.9m3.5m5.2m6.4m4.6m7.0m

Inventories

6.1m

Current Assets

93.1m121.3m121.7m191.0m155.3m270.2m451.5m

PP&E

12.1m10.0m8.2m5.1m6.7m8.1m7.1m

Total Assets

108.1m136.0m139.1m198.2m168.9m279.1m460.4m

Accounts Payable

6.5m5.4m7.0m4.6m10.1m8.6m14.1m

Short-term debt

150.0k18.4m

Current Liabilities

75.9m50.6m52.7m42.4m52.4m69.6m95.9m

Long-term debt

92.1m99.0m104.0m107.3m93.4m

Non-Current Liabilities

117.9m107.3m112.0m113.1m154.4m197.9m144.7m

Total Debt

92.3m99.0m104.0m107.3m95.9m

Total Liabilities

193.9m157.9m164.8m155.6m206.8m267.4m240.6m

Common Stock

92.0k117.0k132.0k142.0k171.0k211.0k

Preferred Stock

Additional Paid-in Capital

437.4m571.3m652.7m711.7m763.3m930.3m1.3b

Retained Earnings

(570.7m)(632.7m)(717.9m)(708.6m)(801.4m)(918.7m)(1.1b)

Total Equity

(85.8m)(21.9m)(25.7m)42.7m(37.9m)11.7m219.7m

Debt to Equity Ratio

-4 x2.5 x0.4 x

Debt to Assets Ratio

0.7 x0.5 x0.2 x

Financial Leverage

-1.3 x-6.2 x-5.4 x4.6 x-4.5 x23.8 x2.1 x

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Cash

72.4m60.4m63.0m49.1m59.6m44.0m65.0m47.2m52.2m46.8m68.1m141.5m56.4m57.3m62.5m65.8m62.8m83.7m295.4m65.1m73.9m130.5m147.1m96.6m

Accounts Receivable

1.0m5.7m4.4m6.0m4.9m2.1m13.5m64.8m62.9m33.9m43.1m32.5m26.6m30.0m44.2m44.4m22.2m31.7m

Prepaid Expenses

4.8m4.2m4.7m3.6m5.1m7.6m10.0m3.1m3.7m6.1m4.3m4.4m6.8m7.2m6.7m7.4m6.8m7.7m3.7m4.6m5.2m17.4m31.5m34.8m

Inventories

4.4m

Current Assets

82.1m64.9m104.1m70.9m114.3m94.2m134.2m128.5m118.1m122.8m150.8m196.6m179.6m191.9m187.5m158.0m263.9m247.0m493.8m453.9m487.8m476.2m530.8m493.9m

PP&E

14.8m14.0m12.9m11.7m11.2m10.7m9.1m8.4m7.8m7.8m8.1m7.5m5.0m5.7m6.5m7.3m7.4m8.5m7.6m7.2m7.6m6.9m6.9m7.0m

Total Assets

99.8m82.2m120.0m85.5m128.4m107.4m152.6m146.3m135.2m135.3m163.6m208.4m186.8m199.9m196.2m166.9m272.2m256.2m502.3m462.8m497.0m484.2m549.0m567.0m

Accounts Payable

4.5m4.9m4.6m4.3m4.7m7.5m3.1m4.0m7.0m5.2m9.3m7.6m6.5m12.1m15.6m5.9m6.5m7.8m8.9m11.0m11.7m14.6m10.4m9.1m

Short-term debt

4.4m150.0k150.0k150.0k10.2m10.8m12.1m12.4m12.7m12.8m

Current Liabilities

93.2m80.0m75.7m66.8m50.3m54.1m51.9m38.3m45.9m56.6m67.9m44.9m49.3m53.0m59.5m64.2m64.4m71.3m90.9m73.6m85.1m84.8m84.2m86.7m

Long-term debt

88.3m90.0m90.9m93.2m94.4m95.3m100.2m101.4m102.7m105.3m106.6m108.0m108.8m110.4m112.0m115.4m117.5m119.4m123.3m93.3m94.6m131.1m132.7m134.2m

Non-Current Liabilities

140.4m129.3m123.1m115.1m109.8m105.7m113.9m113.4m112.6m116.3m109.6m113.4m113.4m141.0m151.5m154.8m155.8m157.2m184.8m147.1m146.8m180.4m179.4m178.7m

Total Debt

92.6m90.2m91.1m93.3m94.4m95.3m100.2m101.4m102.7m105.3m106.6m108.0m108.8m110.4m112.0m115.4m117.5m119.4m123.3m93.3m94.6m131.1m132.7m134.2m

Total Liabilities

233.6m209.3m198.8m181.9m160.1m159.8m165.8m151.7m158.5m172.9m177.6m158.3m162.7m194.0m211.0m219.0m220.2m228.5m275.7m220.7m231.9m265.2m263.6m265.4m

Common Stock

57.0k62.0k89.0k95.0k117.0k117.0k121.0k125.0k126.0k132.0k139.0k140.0k142.0k143.0k143.0k147.0k169.0k170.0k196.0k207.0k210.0k213.0k218.0k221.0k

Preferred Stock

Additional Paid-in Capital

347.5m357.9m428.0m446.6m522.2m523.1m595.7m619.9m626.8m653.9m687.2m696.7m753.5m759.5m761.4m777.7m905.2m916.7m1.2b1.2b1.3b1.3b1.4b1.4b

Retained Earnings

(550.7m)(554.5m)(562.7m)(582.5m)(593.4m)(615.0m)(648.4m)(664.8m)(689.7m)(745.5m)(754.1m)(695.8m)(729.6m)(753.7m)(776.4m)(830.0m)(853.3m)(889.1m)(956.7m)(990.7m)(1.0b)(1.1b)(1.1b)(1.1b)

Total Equity

(133.8m)(127.2m)(78.8m)(96.4m)(31.7m)(52.4m)(13.2m)(5.3m)(23.3m)(37.6m)(13.9m)50.2m24.1m5.9m(14.8m)(52.1m)52.1m27.7m226.6m242.2m265.2m219.1m285.4m301.6m

Debt to Equity Ratio

-7.6 x-19 x-4.4 x-2.8 x4.5 x18.8 x-7.6 x-2.2 x2.3 x4.3 x0.5 x0.4 x0.4 x0.6 x0.5 x0.4 x

Debt to Assets Ratio

0.7 x0.7 x0.8 x0.8 x0.6 x0.6 x0.6 x0.7 x0.4 x0.5 x0.2 x0.2 x0.2 x0.3 x0.2 x0.2 x

Financial Leverage

-0.7 x-0.6 x-1.5 x-0.9 x-4 x-2 x-11.6 x-27.3 x-5.8 x-3.6 x-11.8 x4.2 x7.7 x34 x-13.3 x-3.2 x5.2 x9.2 x2.2 x1.9 x1.9 x2.2 x1.9 x1.9 x

Array BioPharma Cash Flow

Annual

USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(23.6m)(61.9m)(85.3m)9.4m(92.8m)(116.8m)

Depreciation and Amortization

5.1m4.4m4.5m3.7m1.5m2.1m2.2m

Accounts Receivable

(8.5m)4.2m(7.6m)(33.0m)8.0m(805.0k)

Accounts Payable

2.0m(1.3m)1.9m(1.1m)3.9m(1.0m)5.7m

Cash From Operating Activities

(33.5m)(87.1m)(71.7m)(5.8m)(70.1m)(39.4m)(119.8m)

Purchases of PP&E

(1.4m)(2.3m)(2.6m)(2.5m)(3.2m)(3.5m)(1.2m)

Cash From Investing Activities

(18.7m)(16.4m)2.5m(58.0m)66.0m(58.1m)(191.0m)

Long-term Borrowings

(4.3m)(92.7m)(14.5m)

Cash From Financing Activities

60.0m108.4m77.1m50.9m5.0m166.8m299.6m

Net Change in Cash

7.7m4.9m7.9m(12.9m)907.0k69.3m(11.2m)

Interest Paid

7.0m6.6m4.3m4.5m4.5m4.4m4.0m

Income Taxes Paid

2.3m

Quarterly

USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019

Net Income

(3.6m)(7.4m)(15.6m)(11.8m)(22.7m)(44.3m)(15.7m)(32.1m)(57.0m)(27.6m)(36.2m)22.1m(21.0m)(45.2m)(67.8m)(28.6m)(51.9m)(87.2m)(38.0m)(72.0m)(94.9m)(24.8m)(36.2m)(73.7m)

Depreciation and Amortization

1.3m2.6m3.9m1.1m2.3m3.4m1.1m2.4m3.6m876.0k1.8m2.8m473.0k859.0k1.3m475.0k971.0k1.5m577.0k1.1m1.7m533.0k1.1m1.6m

Accounts Receivable

8.6m3.9m5.2m(571.0k)551.0k(3.4m)(7.2m)(26.6m)(44.6m)5.4m(3.8m)6.8m4.7m1.3m(12.9m)(12.3m)9.8m424.0k

Accounts Payable

4.1m488.0k133.0k(1.6m)(1.2m)1.1m(962.0k)(940.0k)2.7m(54.0k)3.6m1.3m2.7m7.1m10.6m(3.4m)(3.6m)(1.1m)1.3m2.5m4.3m4.3m(1.8m)(447.0k)

Cash From Operating Activities

13.6m(6.2m)(23.6m)(21.4m)(50.8m)(73.0m)(1.1m)(34.3m)(49.4m)(18.8m)(16.8m)21.5m(19.2m)(61.5m)(62.6m)(14.6m)(42.2m)(56.7m)(18.0m)(70.2m)(91.2m)(34.8m)(43.4m)(87.4m)

Purchases of PP&E

(433.0k)(926.0k)(1.1m)(804.0k)(1.5m)(2.0m)(198.0k)(725.0k)(1.4m)(483.0k)(1.7m)(2.1m)(411.0k)(1.5m)(2.7m)(1.0m)(1.7m)(3.3m)(24.0k)(212.0k)(1.1m)(265.0k)(843.0k)(1.5m)

Cash From Investing Activities

10.6m14.7m(21.3m)14.3m(17.8m)(11.1m)(10.8m)(25.8m)(11.6m)(3.0m)(15.0m)12.6m19.2m58.2m64.5m1.5m(99.8m)(72.5m)(59.7m)(246.9m)(258.2m)13.7m(32.9m)(84.6m)

Short-term Borrowings

(15.0m)(15.0m)(15.0m)

Long-term Borrowings

(4.2m)(4.2m)(150.0k)(14.5m)(14.5m)

Cash From Financing Activities

38.0k3.7m59.8m361.0k72.4m72.3m16.3m46.6m52.4m45.0k31.3m38.8m664.0k4.8m4.9m22.4m148.2m156.3m247.3m256.1m297.3m36.8m108.7m153.9m

Net Change in Cash

24.3m12.3m14.9m(6.7m)3.8m(11.8m)4.3m(13.5m)(8.6m)(21.8m)(446.0k)72.9m667.0k1.6m6.8m9.2m6.2m27.2m169.5m(60.9m)(52.1m)15.8m32.3m(18.1m)

Interest Paid

1.8m3.5m5.3m1.7m3.5m5.2m124.0k2.1m2.2m121.0k2.2m2.3m121.0k2.2m2.4m130.0k2.2m2.3m89.0k2.2m2.3m1.2m3.2m3.7m

Array BioPharma Ratios

USDQ1, 2012

Financial Leverage

-0.7 x

Array BioPharma Employee Rating

3.533 votes
Culture & Values
3.3
Work/Life Balance
3.7
Senior Management
2.7
Salary & Benefits
3.8
Career Opportunities
3.1
Source